Assembly Biosciences' ABI-4334 demonstrated strong antiviral activity in a Phase 1b trial for chronic hepatitis B, showing a mean HBV DNA decline of 2.9 log10 IU/mL.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.